SCHEMBL30342297

SCHEMBL30342297

CC(C)(C)OC(=O)C12CNCCCC1(C(=O)O)C2

nearest known ligand 0.30

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 1/20 0.30
SLC6A4 P31645 1/20 0.30
SLC6A3 Q01959 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3557213 0.77
SCHEMBL4334068 0.71 CYP2C19 (0.39) SLC6A2SLC6A4SLC6A3
SCHEMBL30271352 0.69
SCHEMBL28683913 0.68
SCHEMBL28755859 0.68 BTK (0.33)
SCHEMBL25386854 0.68
SCHEMBL30538006 0.68
SCHEMBL28683915 0.68
SCHEMBL24447320 0.68 BTK (0.33)
SCHEMBL30660049 0.68

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4408838-A1 DIOXAZINES AND THEIR USE IN TREATMENT OF GBA-RELATED DISEASES Zevra Denmark A/S (DK) 2024-08-07 EP disclosed
CN-118076599-A Dioxazines and their use in the treatment of GBA related diseases 泽拉丹麦有限公司 2024-05-24 CN disclosed
WO-2023053007-A1 DIOXAZINES AND THEIR USE IN TREATMENT OF GBA-RELATED DISEASES KEMPHARM DENMARK A/S (DK) 2023-04-06 WO disclosed